POS0314 Can Methotrexate influence sexual dysfunction in male patients: analysis of the IIEF5 questionnaire and hormonal status
(2023) EULAR 2023 European Congress of Rheumatology — Location: (Italy) Milano (31.May.2023)
Files
2023_EULAR_POS0314.pdf
Open Access - Adobe PDF
- 5.87 MB
Details
- Authors
- Abstract
- BACKGROUND: Methotrexate (MTX) is the anchor drug of Rheumatoid Arthritis (RA) treatment. It is a safe and handy drug, but it has several well-known side effects mainly not severe such as nausea, fatigue, alopecia, or an increase in transaminases. In the last years, sexual dysfunction has been reported as a rare adverse effect of MTX therapy. OBJECTIVES: To explore this, the aim of this study is to evaluate the impact of MTX on erectile function in male patients through the IIEF5 questionnaire and hormonal dosage. METHODS: Male patients affected by inflammatory arthritis (Rheumatoid Arthritis or Psoriatic Arthritis [PsA]) according to the 2010 EULAR/ACR diagnostic criteria for RA and the 2006 CASPAR criteria for PsA and treated with chronic MTX were enrolled. Age-matched patients affected by chronic arthritis not treated with MTX were enrolled as control. Each patient underwent blood collection for a complete serum sexual hormone evaluation. IIEF5 questionnaire which consists of 5 items with a maximum score of 25 was administered to the patients. […]
- Affiliations
Citations
Natalucci, F., Bisseron, S., Sokolova, T., Avramovska, A., Maiter, D., & Durez, P. (2023). POS0314 Can Methotrexate influence sexual dysfunction in male patients: analysis of the IIEF5 questionnaire and hormonal status. Annals of the rheumatic diseases, 82(Suppl 1), 401-402. https://doi.org/10.1136/annrheumdis-2023-eular.3853 (Original work published 2023)